Jonathan Cheng — SPARQNOW

At-a-Glance

Serves as Chief Medical Officer at Systimmune, overseeing the clinical development of novel therapeutics, including ADC candidates and a first-in-class EGFR-HER3 bispecific ADC.
Previously held the role of Senior Vice President, Clinical Oncology Therapeutic Area Head at BMS.
Led the development of multiple novel therapeutics, including pembrolizumab and lenvatinib, as Therapeutic Area Head at Merck.
Authored and led multiple registration-enabling clinical trials, securing health authority submissions and approvals for over a dozen oncology indications.
Holds an Associate Professor position at Fox Chase Cancer Center, where he conducts translational research and sees patients with gastrointestinal malignancies weekly.
Developed novel tumor fibroblasts therapeutics, holding the IND and several patent positions.
Served as an Industry Representative of the Oncology Drug Advisory Committee of the FDA.

Biography

Jonathan Cheng is the Chief Medical Officer at Systimmune, where he is responsible for overseeing the clinical development of the company's entire pipeline of novel therapeutics. His work includes advancing novel ADC candidates and multiple new Investigational New Drug (IND) applications, as well as leading registration-enabling Phase 3 trials for the first-in-class EGFR-HER3 bispecific ADC.